Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Aug;31(8):1210–1215. doi: 10.1128/aac.31.8.1210

Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.

C W Stratton, C Liu, L S Weeks
PMCID: PMC174905  PMID: 2820300

Abstract

Kill-kinetic methods were used to provide data on the bactericidal activity of subinhibitory (0.5x MIC), inhibitory (1x MIC), and suprainhibitory (4x MIC) concentrations of LY146032 against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis. These bactericidal activities were compared with those of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin. LY146032 was among the most active of the antistaphylococcal agents tested, as determined by broth microdilution methods, with all strains being inhibited at concentrations of less than or equal to 1 microgram/ml. Time kill-kinetic studies demonstrated that at 4x MIC, LY146032 was rapidly bactericidal against all strains of staphylococci. Our data show that LY146032 has significant bactericidal activity against staphylococci in comparison with other antistaphylococcal agents. Further evaluation of LY146032 against serious staphylococcal infections is warranted.

Full text

PDF
1210

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bryan C. S., Kirkhart B., Brenner E. R. Staphylococcal bacteremia: current patterns in nonuniversity hospitals. South Med J. 1984 Jun;77(6):693–696. doi: 10.1097/00007611-198406000-00007. [DOI] [PubMed] [Google Scholar]
  2. Coppens L., Hanson B., Klastersky J. Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin. Antimicrob Agents Chemother. 1983 Jan;23(1):36–41. doi: 10.1128/aac.23.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eliopoulos G. M., Thauvin C., Gerson B., Moellering R. C., Jr In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1985 Mar;27(3):357–362. doi: 10.1128/aac.27.3.357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eliopoulos G. M., Willey S., Reiszner E., Spitzer P. G., Caputo G., Moellering R. C., Jr In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986 Oct;30(4):532–535. doi: 10.1128/aac.30.4.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fass R. J., Helsel V. L. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1986 Nov;30(5):781–784. doi: 10.1128/aac.30.5.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Foster J. K., Lentino J. R., Strodtman R., DiVincenzo C. Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies. Antimicrob Agents Chemother. 1986 Dec;30(6):823–827. doi: 10.1128/aac.30.6.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Frongillo R. F., Bianchi P., Moretti A., Pasticci M. B., Ripa S., Pauluzzi S. Cross-resistance between methicillin and cephalosporins for staphylococci: a general assumption not true for cefamandole. Antimicrob Agents Chemother. 1984 May;25(5):666–668. doi: 10.1128/aac.25.5.666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Frongillo R. F., Donati L., Federico G., Martino P., Moroni M., Ortona L., Palumbo M., Pasticci B. M., Pizzigallo E., Privitera G. Clinical comparative study on the activity of cefamandole in the treatment of serious staphylococcal infections caused by methicillin-susceptible and methicillin-resistant strains. Antimicrob Agents Chemother. 1986 May;29(5):789–796. doi: 10.1128/aac.29.5.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Knapp C. C., Washington J. A., 2nd Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin. Antimicrob Agents Chemother. 1986 Dec;30(6):938–939. doi: 10.1128/aac.30.6.938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Libman H., Arbeit R. D. Complications associated with Staphylococcus aureus bacteremia. Arch Intern Med. 1984 Mar;144(3):541–545. [PubMed] [Google Scholar]
  12. Lowy F. D., Hammer S. M. Staphylococcus epidermidis infections. Ann Intern Med. 1983 Dec;99(6):834–839. doi: 10.7326/0003-4819-99-6-834. [DOI] [PubMed] [Google Scholar]
  13. Menzies R. E., Cornere B. M., MacCulloch D. Cephalosporin susceptibility of methicillin-resistant, coagulase-negative staphylococci. Antimicrob Agents Chemother. 1987 Jan;31(1):42–45. doi: 10.1128/aac.31.1.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sabath L. D. Mechanisms of resistance to beta-lactam antibiotics in strains of Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):339–344. doi: 10.7326/0003-4819-97-3-339. [DOI] [PubMed] [Google Scholar]
  15. Sheagren J. N. Staphylococcus aureus. The persistent pathogen (first of two parts). N Engl J Med. 1984 May 24;310(21):1368–1373. doi: 10.1056/NEJM198405243102107. [DOI] [PubMed] [Google Scholar]
  16. Sorrell T. C., Packham D. R., Shanker S., Foldes M., Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):344–350. doi: 10.7326/0003-4819-97-3-344. [DOI] [PubMed] [Google Scholar]
  17. Thornsberry C., McDougal L. K. Successful use of broth microdilution in susceptibility tests for methicillin-resistant (heteroresistant) staphylococci. J Clin Microbiol. 1983 Nov;18(5):1084–1091. doi: 10.1128/jcm.18.5.1084-1091.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Verbist L. In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci. Antimicrob Agents Chemother. 1987 Feb;31(2):340–342. doi: 10.1128/aac.31.2.340. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES